Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxue Qingnao Pill plus amlodipine for grade 1 hypertension
ChiCTR1900022470Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Yangxueqingnao and amlodipine in hypertension (HTN) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Systolic blood pressure and Diastolic blood pressure. Planned start May 2019; status: not yet recruiting.
02
Drugs
Yangxueqingnaoamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR1900022470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022470.